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Abstract
Atypical or second-generation antipsychotics (SGAs) are a vital part of the management
of many psychotic disorders, as well as behavioral and psychological symptoms. However, these
medications have serious cardiometabolic complications, such as an increase in obesity, glucose
intolerance, dyslipidemia, and hypertension, and can place the patient at serious risk for
cardiovascular disease. The American Diabetes Association (ADA) and the American Psychiatric
Association (APA) recommend clinical guidelines for metabolic screening, which requires the
regular monitoring of patients treated with SGAs (ADA, 2004). The goal of this quality
improvement project was to 1) implement a metabolic screening protocol based on ADA and
APA guidelines for patients admitted to an acute psychiatric hospital who were treated with
second-generation antipsychotics and 2) increase healthcare personnel awareness of metabolic
monitoring guidelines and metabolic syndrome. This quality improvement project was
implemented at an inpatient behavioral hospital in New England. A protocol for the monitoring
of metabolic disturbances was placed in thirty patients’ medical charts, who were age eighteen
and over, had been prescribed SGAs, and had been taking the medication daily since the
admission to the hospital. Twenty-one psychiatric mental health staff members attended the
educational interventions that were conducted by the author of the project
A retrospective chart review was performed post-intervention to assess guideline
adherence by comparing the percentage of tests ordered pre-intervention versus the during the
post-intervention period. Data were collected over a three-month period starting from November
2018 until January 2019. The healthcare personnel awareness of metabolic monitoring guidelines
and metabolic syndrome have been evaluated by a survey. After the intervention period, there
were slight increases in the numbers of orders for hemoglobin A1c and lipid panel, but rates of
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other baseline monitoring parameters (such as weight and blood pressure) remained the same or
did not improve. The waist circumference was one of the indicators that had not been measured,
even after the implementation of the screening protocol.
Keyword: atypical antipsychotics, metabolic syndrome, guidelines, monitoring, diabetes,
dyslipidemia, cardiovascular disease
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IMPLEMENTING A PROTOCOL TO MONITOR CARDIOMETABOLIC RISK IN
PATIENTS PRESCRIBED ATYPICAL ANTIPSYCHOTICS
Introduction
Second-generation antipsychotics (SGAs) medications brought new hope in the field of
psychiatry, as they offered important benefits for people with mental health illness. Furthermore,
they are associated with fewer complications of the extrapyramidal syndrome, tardive
dyskinesia, and elevated prolactin, when compared with “typical antipsychotics” (Gill, Teong,
Gee, Wen & Jawan, 2012; Newcomer & Haupt, 2006). However, soon after their introduction,
several undesirable side effects, such as significant weight gain, insulin resistance, impaired
glucose tolerance, and dyslipidemia, surfaced. All of these symptoms are associated with the
development of metabolic syndrome, which is a key risk factor for cardiovascular disease (Ba,
Su, Chen, Chen & Chang, 2013).
Background
Atypical Antipsychotics. In 1950, the introduction of the first typical antipsychotic,
chlorpromazine (Thorazine) into clinical practice revolutionized the treatment of schizophrenia
(De Hert, Vancampfort, Correll, Mersken, van Winkel & Mitchell, 2012). After a historic study
completed by Elkes and Elkes in 1954, which was randomized and placebo-controlled,
chlorpromazine started being accepted by psychiatrists all over the world. By the end of 1975,
there were fifteen antipsychotic drugs available in the United States, and about forty worldwide
(Ramachandraiah, Subramaniam, & Tancer, 2009). The arrival of clozapine, the first atypical
antipsychotics, turned a new page for the treatment of schizophrenia. This medication was not
associated with extrapyramidal symptoms seen with typical antipsychotics. Clozapine became
the model for a new class of atypical antipsychotic drugs, and thirty years later, risperidone was
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created, which became the most commonly prescribed antipsychotic medication in the United
States (Perese, 2012).
Atypical antipsychotics are a vital part of medical management for a wide range of
psychiatric disorders and behavioral disturbances. In addition to schizophrenia, atypical
antipsychotics are often prescribed for the treatment of aggressive and disruptive behavior,
bipolar mania and depression, unipolar severe depression that does not respond to standard
antidepressant treatment, and Tourette’s syndrome. Nowadays, atypical antipsychotics are widely
used, especially among children and adolescents (De Hert et al., 2012) and their off-label usage
is also seen in many older patients suffering from dementia.
Antipsychotics are divided into first-generation “typical” drugs that treat the positive,
but not the negative, symptoms associated with psychosis (schizophrenia), and secondgeneration agents, called atypical antipsychotics, which have fewer extrapyramidal symptoms
(EPS) and tardive dyskinesia (TD) symptoms, when compared with the typical antipsychotics.
Although atypical antipsychotics do not exhibit the side effects of the typical antipsychotics to
the same degree, some of them have a tendency to cause weight gain, as well as cardiovascular
and metabolic changes, and insulin resistance (De Hert et al., 2012). Patients with the first
episode of schizophrenia, those who are antipsychotic drug-naïve, children, and adolescents are
especially at risk for developing metabolic disturbances and obesity (De Hert et al., 2012).
Atypical or second-generation antipsychotics (SGAs) contribute significantly to
cardiometabolic and endocrine adverse symptoms constituting metabolic syndrome (MetS)
(Newcomer & Haupt 2005). Metabolic syndrome is a group of risk factors, including
dysglycemia, hypertension, dyslipidemia, and central obesity, that is associated with the
development of cardiovascular disease (Alberti, Zimmet, & Shaw, 2005). Metabolic syndrome is
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a leading cause of increased morbidity and mortality in patients who also suffer from
schizophrenia (Riordan, Antonini, & Murphy, 2011). Metabolic syndrome has substantial cost
implications for society; however, ongoing patient monitoring of simple laboratory and clinical
measures can help decrease adverse effects, improve patients’ quality of life, and reduce
healthcare costs.
With the development and introduction of the atypical antipsychotic medications, a new
era in the treatment of psychiatric disorders began. The first in this class, clozapine (Clozaril),
fell quickly out of favor in the beginning due to drug-induced agranulocytosis. During the 1990s,
olanzapine (Zyprexa), risperidone (Risperdal), and quetiapine (Seroquel) were introduced, and
ziprasidone (Geodon) and aripiprazole (Abilify) were introduced ten years later, during the
2000s. Paliperidone (Invega) was FDA -approved in 2006. Atypical antipsychotics soon
constituted the first-line treatment for schizophrenia, due to the decreased incidence of
extrapyramidal side effects (EPS) (Farah, 2005), tardive dyskinesia (TD), and the absence of
prolactin elevation (Seeman, 2002).
Since their introduction, atypical antipsychotics have been prone to both on-label and offlabel usage due to their many notable benefits. Despite their important role in the treatment of
many psychiatric disorders, it was noted that these agents have the potential to cause significant
metabolic disturbances, such as an increase in obesity, glucose intolerance, dyslipidemia and
hypertension (Correll, Frederickson, Kane, & Manu 2007).
It is still uncertain why some of the atypical antipsychotics carry higher risks for
metabolic syndrome than others. Apparently, the cardiometabolic complications vary with
respect to receptor pharmacology that suggests common pathophysiological mechanisms. For
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example, olanzapine and clozapine, two drugs that are known to cause the largest weight gain,
have a high affinity for 5-HT2C and histamine H1 receptors (Reynolds & Kirk, 2010).
In 2004, the American Diabetes Association (ADA), the American Psychiatric
Association (APA), the American Association of Clinical Endocrinologists (AACE), and the
North American Association of the Study of Obesity (NAASO) acknowledged the correlation
between atypical antipsychotics and the development of metabolic syndrome, and also provided
recommendations for the use and monitoring of these agents (ADA, 2004). The report
emphasized that prescribers should evaluate the risks and benefits of prescribing specific atypical
antipsychotics. ADA and APA statement recommended routine monitoring frequencies for the
weight (BMI), waist circumference, blood pressure (BP), fasting plasma glucose, and fasting
lipid profile (ADA, 2004).
Metabolic Syndrome. The criteria for metabolic syndrome, which is sometimes referred to as
syndrome X, are diverse and a standard definition does not exist. The World Health Organization
(WHO), the European Group for the Study of Insulin Resistance, and the National Cholesterol
Education Program Adult Treatment Panel (NCEP ATP) III agree that the base components of
metabolic syndrome are obesity, insulin resistance, dyslipidemia, and hypertension (Riordan et
al., 2011). The International Diabetes Federation (IDF) proposed a set of metabolic syndrome
criteria that include weight gain and hypertriglyceridemia, along with increased glucose and lowdensity lipoprotein cholesterol levels. Central obesity is a major component among the proposed
sets of symptoms, with different waist circumferences for different ethnicity groups, along with
triglyceride levels higher than 150 mg/dl; HDL cholesterol lower than 40 mg/dl in men or lower
than 50 mg/dl in women; systolic blood pressure higher than 130 mmHg and diastolic blood
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pressure higher than 85 mmHg; and fasting plasma glucose higher than 100 mg/dl (Alberti
Zimmet & Shaw 2005). The IDF metabolic syndrome criteria are shown in Table 1.
The National Institute of Health (NIH) (2001) defined metabolic syndrome as “a
combination of risk factors that puts the individual at risk for cardiovascular disease” (NIH,
2001). Overwhelming evidence shows that metabolic syndrome can increase the risk of
developing type 2 diabetes mellitus and can increase both the ten-year risk of coronary heart
disease, three-to-six-fold (Bobes et al., 2007; De Hert et al., 2012), and the mortality rate from
cardiovascular disease (Daumit, 2008). Prospective longitudinal studies reveal that the
occurrence of metabolic adverse effects (such as weight gain, hyperglycemia, hypertension, and
dyslipidemia) in patients increase significantly after the patient’s initial exposure to atypical
antipsychotic medications (De Hert et al., 2012; Foley & Morley, 2011).
Patients with major mental illness have the same modifiable risk factors for
cardiovascular disease and developing metabolic syndrome as the general population such as
smoking, unhealthy lifestyles, diet, and a sedentary lifestyle or lack of physical activity (Hasnain
et al., 2009). However, some researchers suggested that atypical antipsychotic drugs induce
weight gain that is responsible for impaired glucose metabolism, which is independent of
adiposity, and glucose and lipid metabolism abnormalities may occur without weight gain
(Hasnain et al., 2009).
Impaired glucose metabolism and insulin resistance were the first abnormalities to be
reported in patients with schizophrenia and bipolar disorders receiving atypical antipsychotic
medications; however, weight gain is the most noticeable and distressing syndrome among
patients. Different atypical antipsychotics are associated with varying effects on body weight,
plasma glucose, and lipid levels. Overwhelming evidence shows that an increase in adipose
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tissue is associated with a decrease in insulin sensitivity, which contributes to increases in plasma
glucose and lipids and a higher risk for diabetes and cardiovascular diseases.
In 2006, John Newcomer and Dan Haupt reviewed evidence showing that treatment with
antipsychotic medications (particularly with atypical antipsychotics) can be associated with
weight gain, insulin resistance, hyperglycemia, dyslipidemia, and diabetes (Newcomer & Haupt,
2006). The authors identified relevant publications through a search of MEDLINE from the years
1975 to 2006. They found that some of the atypical antipsychotics are associated with moderate
increases in body weight (amisulpride, ziprasidone, and aripiprazole); however, others have a
significant risk for weight gain and disordered glucose and lipid metabolism (olanzapine and
clozapine) (Newcomer & Haupt, 2006). The SGAs side effects are shown in Table 2.
Differential metabolic profiles of atypical antipsychotics were also suggested by other
researchers. The researchers involved in the Clinical Antipsychotic Trials in Intervention
Effectiveness (CATIE) have shown a significant increase in the prevalence of metabolic
syndrome for olanzapine and quetiapine over three months but a decrease for ziprasidone (Meyer
et al., 2008). Olanzapine was associated with the largest mean increase in waist circumference,
subsequent weight gain, and significant changes in fasting triglycerides (Meyer et al., 2008).
Saddichha and colleagues conducted an extensive prospective randomized, double-blind
controlled study, including the measurement of waist circumference, blood pressure, triglyceride,
high-density lipoproteins, and fasting blood sugar levels on patients with first-episode
schizophrenia who received either first-generation haloperidol, or second-generation olanzapine
or risperidone (Saddichha, Manjunath., Ameen & Akhtar, 2008). The analysis shows that the
prevalence of MetS in a patient with schizophrenia was at least five times higher when compared
to the matched healthy control group. The highest prevalence of MetS had olanzapine at twenty
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to twenty-five percent, followed by risperidone at nine to twenty-four percent, and haloperidol at
zero to three percent (Saddichha et al., 2008).
The most noticeable sign of MetSyn is weight gain, and atypical antipsychotics have been
frequently cited for causing it (Lieberman et al., 2004). Long-term treatment with these agents
can cause weight gain from about one kilogram over one year with aripiprazole and ziprasidone;
two to three kilograms with quetiapine and risperidone; and over six kilograms with olanzapine
(Newcomer et al., 2006). Kahn and colleagues conducted a twelve-month open randomized
clinical trial for patients with the first episode of schizophrenia treated with second-generation
antipsychotic drugs (amisulpride, olanzapine, quetiapine, and ziprasidone) and found that there
was notable weight gain, from 4.8 kg to 9.7 kg (Kahn et al., 2008).
Insulin Resistance. Another concern about treatment with atypical antipsychotics is an increased
risk of insulin resistance, hyperglycemia, and diabetes. A population-based study associated with
an increased risk of type 2 diabetes mellitus in patients treated with atypical antipsychotics
versus control patients without schizophrenia was conducted by Liao and colleague (Liao et al.,
2011). Authors reported that in the Cox models, significance adjusted hazard ratios (HR)
associated with second-generation antipsychotics were 1.82 (95% confidence interval (CI) 1.302.55) for diabetes and 1.41 (95% CI 1.09-1.83) for hyperlipidemia. A ten-year nationwide
population-based prospective cohort study using a nationwide database with a large sample size
including patients with bipolar disorders (BD), major depressive disorder, and schizophrenia
showed an increase in metabolic disturbances that required initiation of diabetic and
hyperlipidemia medications, especially among patients with BD (HR of 1.506, 95% CI: 1.1072.047) and schizophrenia (HR of 1.154, 95% CI: 1.002-1.329).
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Problem Statement
Atypical, or second-generation antipsychotics, can lead to serious cardio-metabolic disturbances,
such as weight gain, dyslipidemia, and glucose intolerance, and can increase the mortality from
cardiovascular disease. Baseline and ongoing monitoring are recommended for patients
prescribed atypical antipsychotic medications in order to reduce the risk and ensure the wellbeing of the patients.
Organizational “Gap” Analysis of Project Site
The goal of this project was to help identify the existing gap between the current practice
of tests ordered in patients treated with SGAs, according to guideline recommendations, and to
propose corrective action, with the end goal of implementing a protocol for metabolic syndrome
monitoring. Donabedian’s conceptual models align well with the gap analysis and can serve as a
framework for this project (Davis-Ajami, Costa & Kulik, 2014). Donabedian’s structure, process,
and outcomes framework incorporate clinical and patient factors as well as system and
institutional factors and serves as a link between care intervention, outcomes and effectiveness
evaluations (Davis-Ajami et al., 2014).
All atypical antipsychotics provide a warning about the risk of hyperglycemia and
diabetes, as well as suggestions for regular monitoring of plasma glucose; however, very little
data is available about adherence to these monitoring recommendations (US Food and Drug
Administration, 2004). Inconsistencies with assessing the patient and the lack of adherence to
monitoring for cardio-metabolic syndrome symptoms can also be problematic. The research
suggests that in some clinics, less than one-third of the patients prescribed atypical antipsychotics
undergo any blood glucose or lipid testing (Riordan et al., 2011). In addition to psychotic
disorders, atypical antipsychotics are often prescribed off-label for the treatment of aggressive
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and disruptive behaviors in different age groups by primary care providers who have limited
knowledge about guidelines and monitoring requirements (Mitchell, Delaffon, Vancampfort,
Correll & De Hert, 2011).
Things are not any different at the project site. There is no available protocol for
metabolic syndrome monitoring for patients who are being prescribed atypical antipsychotics;
furthermore, prescribers do not adhere to guidelines for monitoring their patients as gap and
SWOT analyses showed as you can see in Table 3.
Review of the Literature
The focus of this literature review was on metabolic complications that arise when
atypical antipsychotics were administered, and guidelines for the monitoring of metabolic risk in
people treated with these agents. Databases and websites that have been reviewed included
PubMed, CINAHL, Cochrane Reports, Agency for Healthcare Research and Quality (AHRQ),
and Web of Science. Search terms used included: atypical antipsychotics, psychiatric disorders,
metabolic syndrome, cardiovascular risk, and guidelines. Inclusion criteria consisted of full-text
articles published between 2000 and 2017 in the English language, concerning adults greater
than eighteen years old. The initial search using just two keywords, SGAs, and MetSyn, yielded
14,013 articles and guidelines. The search was further narrowed down to 242 publications by
adding more keywords: guidelines, monitoring, diabetes, dyslipidemia, and cardiovascular
diseases. The final search yielded forty-three articles and was performed by applying filters for
age (above eighteen years old), language (English), and articles that were published in the past
fifteen years.
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Level 1 Evidence: Case Reports and Uncontrolled Observational Studies
Evidence from case reports, prospective observational studies, retrospective database
analyses, and controlled experimental studies suggest a strong link between atypical
antipsychotics and adverse effects on glucose and lipid metabolism (Newcomer & Haupt, 2006).
The majority of metabolic complications occur within the first six months after the initiation of
treatment and include substantial weight gain, hyperglycemia, metabolic acidosis, ketosis, and
diabetic ketoacidosis-related deaths. All these complications are more frequently associated with
clozapine (Clozaril) (Koller & Doraiswamy, 2001), olanzapine (Koller, Schneider, Bennett &
Dubitsky, 2002), and risperidone treatments (Koller, Cross, Doraiswamy & Schneider, 2003).
There is little evidence that ziprasidone, amisulpride, and aripiprazole cause such adverse effects.
A case report for olanzapine, risperidone, and quetiapine, that included data from the
Federal Drug Administration (FDA) and Med Watch Drug Surveillance System, from 1999 to
2001 and 2002, reported high rates and incidents of diabetic ketoacidosis, hyperglycemia,
metabolic acidosis, pancreatitis, and new-onset diabetes associated with use of these atypical
antipsychotic medications (Koller et al., 2001, 2002,2003).
Level 2 Evidence: Observational database Analyses
Two-thirds of observational database analyses studies report a connection between some
atypical antipsychotic medications and weight gain, as well as a consequential increased risk for
diabetes mellitus (Newcomer & Haupt, 2006). Newcomer and colleagues conducted a
metanalytic review of the relevant literature in an effort to determine the relationship between
antipsychotic treatment and risk for diabetes (Newcomer & Haupt, 2006). They searched
MEDLINE and Current Contents from January 1990 to September 2004 for all relevant
publications on studies using atypical antipsychotics for the treatment of different psychiatric
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disorders. Their analysis consistently shows that clozapine and olanzapine are the two
antipsychotics that cause an increased risk for diabetes most often.
Level 3 Evidence: Controlled Experimental Studies and Randomized Clinical Trials
Long-term schizophrenia trials using different atypical antipsychotics demonstrated
statistically significant increases in fasting glucose and insulin levels with olanzapine and
clozapine therapy and no significant changes with ziprasidone and aripiprazole (Pigott, Carson,
Saha, Torbeyns, Stock, & Ingenito, 2003; Reynolds & Kirk,2002). In an eight-week randomized,
double-blind trial of 157 patients with schizophrenia treated with clozapine, olanzapine,
risperidone, or haloperidol conducted by Lindenmayer and colleagues, the authors found that at
the end of week six, there was a significant increase in mean glucose and cholesterol levels in
patients who received olanzapine, and at the end of the eight-week period, there were increases
in glucose and cholesterol levels in patients who received clozapine (Lindenmayer et al., 2003).
Monitoring Guidelines
The screening and monitoring of metabolic complications when atypical antipsychotics
were administered became a focus for many researchers, and different national and international
organizations have developed their own guidelines for monitoring and managing the risk of these
complications. The guidelines, defined as “systematically developed statements to assist
practitioner and patient decisions about appropriate healthcare for specific clinical
circumstances” (Institute of Medicine, 1992), is considered a good option for translating research
into clinical practice (De Hert et al., 2011).
In November 2003, the ADA, the APA, the AACE, and the NAASO reviewed all
available data on the metabolic effects of atypical antipsychotic medications and established a
strong link between their use and the risk of developing the metabolic syndrome during their
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conference (Riordan et al., 2011). The majority recommended a baseline screening and ongoing
monitoring of metabolic status and cardiovascular risk factors in patients treated with secondgeneration antipsychotic medications. The baseline screening measures when the atypical
antipsychotic medication is initiated and includes body mass index (BMI), waist circumference,
blood pressure, fasting plasma glucose, fasting lipid profile, and a personal and family history of
metabolic syndrome disturbances. If the patient has one or more of the following abnormalities,
initiation of the treatment is recommended: overweight (BMI 25.0-29.9), obesity (BMI>30),
prediabetes (fasting plasma glucose (FPG) 120-125 mg/dl), diabetes (fasting plasma glucose
>126 mg/dl), hypertension (blood pressure (BP)>140/90 mmHg), or dyslipidemia (Rabia, 2007).
The consensus also recommended ongoing monitoring for factors such as personal
history, weight (BMI), waist circumference, BP, FPG, and fasting lipid profile at baseline, four
weeks, eight weeks, twelve weeks, quarterly, annually, and every five years (Riordan et al.,
2011). The ongoing monitoring protocol is shown in Table 4. This guideline is based on lifestyle
management and is very easy to use in primary care settings. The metabolic syndrome time
monitoring tool that the guideline proposed is an important instrument for the management of
metabolic disturbances, and the most valuable evidence-based resource for this DNP project.
From the review of the literature, it is obvious that there are significant research and
many practice guidelines for managing metabolic syndrome and metabolic complications. In
2011, De Hert and colleagues published a systematic review and quality assessment of all
guidelines and recommendations for monitoring a cardiovascular risk in patients with
schizophrenia published between 2000 and 2010, using the Appraisal of Guidelines for research
and evaluation (AGREE) (De Hert et al., 2011). From a total of fifty-four guidelines that the
authors found, eighteen were identified for AGREE evaluation. All the guidelines covered
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diabetes and cardiovascular disease risk in patients treated with antipsychotics. All guidelines
included monitoring weight, body mass index (BMI), and fasting glucose; some included
measurements of waist circumference and assessment of fasting lipids; and the more recent
guidelines were more detailed and included evaluations of personal and family history, and
cardiovascular risk factors (De Hert et al., 2011). Based on their review of the guidelines, the
authors concluded that all patients with schizophrenia treated with SGAs should be under the
active care of a medical physician, and they proposed a monitoring protocol. The protocol is
shown in Table 4.
Despite the recommendations, there is an inconsistency in the implementation of these
guidelines, and adherence to them by healthcare providers (Riordan et al., 2011).
Sankaranarayanan, A. & Castle, D. (2012) found that diabetes and dyslipidemia screening among
patients treated with atypical antipsychotic drugs was low and did not improve after the
recommendations from the ADA and APA. They reported that the best rates are around sixty
percent coverage for the routine monitoring of blood glucose and lipids, and fifty-four percent
for weight management.
When left untreated, metabolic syndrome can lead to serious cardiovascular
complications and death. The researchers found that the risk for coronary heart disease and
stroke was tripled, and cardiovascular mortality rates increase significantly among individuals
diagnosed with metabolic syndrome (Lieberman et al., 2004). Despite ADA, APA, AACE, and
NAASO recommendations for screening and the ongoing monitoring of patients receiving
atypical antipsychotics, many healthcare providers do not consistently adhere to these guidelines
(Cohn & Sernyak, 2013).
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Theoretical Framework/Evidence-Based Practice Model
The project was based on the Donabedian conceptual framework for the examination of
health services and the evaluation of the quality of health care (Fig.1). Avedis Donabedian was a
professor and a healthcare researcher at the University of Michigan, and he proposed that an
improvement in the structure of care should lead to an improvement in clinical processes that
would improve patient outcomes. His article “Evaluating the Quality of Medical Care,”
published 1966, became the foundation of his body of work on the theory and practice of the
quality assurance of health services research. During his career, he developed methods to
measure the quality of healthcare, and in his landmark 1966 article, Donabedian suggests a triad
of structure, process, and outcome to evaluate the quality of healthcare (Ayanian, 2016). He
defined the structure as all factors delivered to the patients that directly affect their care,
including the facility, equipment, human resources, training and qualification of the providers.
The processes are technical processes or interpersonal processes, and they comprise the sum of
all actions in terms of the way in which care is delivered. Lastly, the outcome is the effects on
patients, changes to health status or knowledge, and patient satisfaction (Donabedian, 1966).
The structure, according to Donabedian, includes all the factors that affect the context in
which care is delivered. This includes the facility, equipment, and human resources
(psychiatrists, mental health nurse practitioners, and nurses), as well as organizational
characteristics such as staff training and Joint Commission accreditation of the hospital. Using
Donabedian’s conceptualization of quality of care, the present quality improvement project
operationalized structure as hospital assets of psychiatrists, mental health care nurse
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practitioners, and staff nurses’ knowledge about metabolic syndrome monitoring guidelines and
recommendations.
The process is the sum of all actions that make up healthcare. These include diagnosis,
treatment, patient educations, and how care is delivered. The protocol for monitoring metabolic
syndrome abnormalities that this quality improvement project proposes is a part of the process
that will improve patients’ outcome. Early recognition and the reduction of metabolic syndrome
abnormality in patients treated with SGAs by screening and testing will improve their quality of
life.
Goals, Objectives and Expected Outcomes
The purpose of this quality improvement project was to provide information on metabolic
screening and to implement a protocol for the metabolic screening and monitoring of patients
who are prescribed second-generation antipsychotics, as well as to assess whether this protocol is
followed up by the prescribers, which was evidenced by increased rates of relevant testing.
The objectives:
1. Increased awareness of metabolic screening guidelines among mental health care staff.
2. Increase psychiatric prescribers’ readiness to implement a metabolic screening protocol
based on guidelines as evidenced by the increased number of testing for HgA1c, fasting lipids,
blood pressure, and waist circumference.
The quality improvement project followed Donabedian quality improvement conceptual
model as a framework (Fig.1). The DNP student utilized the hospital base and organization, and
mental health staff (structure) to implement a screening metabolic protocol (process) in order to
improve the patient’s health and clinical outcomes.
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Methods
This quality improvement practice project aimed to increase the awareness by the
psychiatric mental health providers and staff about metabolic complications with SGAs and their
adherence to guidelines for metabolic monitoring of patients on atypical antipsychotics. During
the project the following took place:
An informational session was provided to twenty-one mental health care prescribers and
nursing staff who were involved in the monitoring and management of selected patients treated
with SGA, as an educational component to introduce the APA and the ADA guideline of
metabolic syndrome testing, and to identify the project objective (Appendix A).
Each psychiatrist, PMHNP and staff nurse was encouraged to take a survey to determine
their knowledge of existing guidelines for metabolic syndrome monitoring, self-efficacy, and
possible barriers to following up the guideline (Appendix B).
The protocol (Appendix C) was then placed in charts (the hospital uses paper charts) of
the patients admitted to the institution between September 30, 2018, and December 31, 2018
with a goal of including up to thirty psychiatric patients who were adults (age eighteen and
greater) and were treated with atypical antipsychotic medications.
Project Site and Population
This project was conducted at a behavioral health hospital in New England, a 120-bed
inpatient hospital with three adult units, one geriatric unit, and one adolescent unit that mandates
twenty-four-hour coverage by board-certified psychiatrists. The hospital serves eighty-four
towns and cities. These are the only counties in the nation where Portuguese Americans make up
the plurality of the population including the Portuguese Americans, the Brazilians Americans,
and the Portuguese Cape Verdean population. The region is home to approximately one million
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people residing in over 1,300 square miles. The area is ethnically and linguistically diverse with
Portuguese speakers well represented. Most mental health services are provided through health
insurance, such as Medicaid or private insurance. Despite the fact that more than sixty-two
percent of the population is employed, many of the patients of Portuguese and Brazilians descent
served by this hospital are poor or homeless (US Census). Many of them have mental health
issues ranging from schizophrenia and bipolar disorders to PTSD, alcohol and substance abuse.
Implementation Plan
At the pre-implementation phase, the DNP student offered a 45-minute educational
session to nine psychiatric providers and twelve staff nurses working with the selected patients,
to review the ADA/APA guideline recommendations for metabolic screening in patients treated
with SGAs. Information was provided about the metabolic complications, the importance of
screening, and the proposed screening protocol. By the end of the session, health care personnel
were invited to take a survey with three closed-ended questions and two open-ended questions to
test participants’ knowledge about guidelines for the monitoring of metabolic syndrome in a
patient treated with SGAs and anticipated barriers.
The author of the project created a metabolic monitoring protocol based on the
recommendations made by the American Diabetic Association (ADA), American Psychiatric
Association (APA), American Association of Clinical Endocrinologists (AACE), and North
American Association of the Study of Obesity (NAASO). This protocol was placed during the
implementation phase in the thirty paper charts of patients aged eighteen years old and above,
who had been on at least one scheduled atypical antipsychotic.
The protocol was placed in the thirty selected patients’ charts during the time period from
October 25, 2018, until December 30, 2018. The review of the medical records of those patients
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who have had the protocol was carried out on a weekly basis between December 15, 2018, and
January 31, 2019, by the DNP student. Based on national and international guidelines, the DNP
student used the following standards for a monitor for metabolic disturbances in the selected
patients’ charts:
1. All patients on atypical antipsychotics should have their BMI, waist circumference,
blood pressure, lipid level, and fasting or random glucose level tested at baseline and at
three, six, and twelve months.
2. Results are abnormal and should be acted on if the following is noted in a patient:
-

BMI ≥30 kg/m²

-

waist circumference ≥94 cm for male and ≥80 cm for female

-

total cholesterol ≥240 mg/dl (4.6 mmol/l)

-

triglycerides ≥ 150 mg/dl (1.7 mmol/l)

-

high-density lipoprotein cholesterol < 40 mg/dl (1.03 mmol/l) for males and <

50mg/dl (1.29 mmol/l) for females
-

systolic blood pressure ≥130 mmHg

-

diastolic blood pressure ≥85 mmHg

-

fasting plasma glucose ≥100 mg/dl (5.6 mmol/l)

-

random plasma glucose ≥110 mg/dl (6.6 mmol/l).

3. All patients with abnormal results should be referred to the medical clinical specialist.
Charts of the patient who were prescribed SGAs were identified from the three adult
inpatient units between September 1, 2018, and November 30, 2018. A chart review was
performed by the DNP student (who is employed as a nurse at the facility), starting in September
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2018, to identify all patients over the age of eighteen receiving atypical antipsychotics, in order
to identify patients for monitoring.
A list of all patients’ charts (who were eighteen years and older) admitted to the three
adult units at the Behavioral Hospital and prescribed atypical antipsychotics was created at the
beginning of the implementation phase. Every eligible patient’s chart was assigned a number and
this number was used for identification during the implementation of the screening protocol. The
list of the charts and their assigned numbers were kept in a secure location, in a locked drawer,
that only the author of the project had access to, in order to protect patients’ information in
accordance with HIPPA (US Department of Health and Human Services, 2003). Table 5 shows a
working data sheet that was created by the DNP nurse student for the collection of the
information.
During the implementation phase, the screening metabolic monitoring protocol was
placed in the medical record of the thirty eligible patients’ charts, in the physician orders section.
The number of parameters completed at baseline (weight, BMP, waist circumference, blood
pressure, fasting glucose level, and fasting lipid levels) was recorded. During the postimplementation phase, after the screening protocol was placed in the patient’s chart, the number
of ordered tests (HgA1c, lipids) was recorded along with weight, BMI, blood pressure, and waist
circumference.
Ethical Considerations
All participants were protected by the Health Insurance Portability and Accountability
Act of 1996 (HIPAA), which, among other guarantees, protects the privacy of patients’ health
information (Modifications to the HIPAA Privacy, Security, Enforcement, and Breach
Notification Rules, 2013). Additionally, the DNP student carefully conducted this project
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following the Standards of Care for practice. All information collected as part of evaluating the
impact of this project did not include any potential patient identifiers. The risk to patients
participating in this project as reviewing their charts was no different from the risks of patients
receiving standard psychiatric care.
Participant confidentiality was assured by coding the participants using individual
identification numbers and keeping this list of participants with identifying numbers in locked
filing cabinets in the hospital, only accessible to the DNP student. All electronic files containing
identifiable information were password protected to prevent access by unauthorized users, and
only the DNP student had access to the passwords.
This project consisted of implementing a protocol for metabolic syndrome monitoring of
patients receiving SGAs and their charts review, and there were no risks to the participant;
patients, and mental health prescribers, and nursing staff. The health care providers had a choice
to participate in the explanatory meeting about the purpose of this quality improvement project.
The patients’ charts review was performed by the DNP student and the identity of patients was
not shared with administration.
The project was reviewed and approved by The New England Behavioral Health
administration and management, and by Human Research Protection Office at the University of
Massachusetts Amherst. (Appendix D).
Data Analysis
Planning activities for this practice quality improvement project began in September
2018. The main objectives were:
(1) To utilize a screening protocol for metabolic syndrome abnormalities in patients
treated with atypical antipsychotics in an inpatient psychiatric hospital.
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(2) To increase the monitoring for metabolic syndrome by participants as evidenced by
the increased number of laboratory testing (HgA1c and Lipids).
(3) To increase healthcare providers’ awareness about MetSyn and adverse effects of
SGAs
In the initial planning process, a meeting with the clinical director and chief medical
officer at the behavioral health hospital was held to discuss and determine the need of developing
and implementing a protocol for metabolic syndrome monitoring for a patient treated with
atypical antipsychotic medications.
The project proposal was reviewed and approved in September 2018 by the management
of the behavioral hospital. After thorough research of the evidence-based literature, a protocol for
metabolic syndrome monitoring was developed by the author of the project based on ADA and
APA guidelines (ADA, 2004).
The data collected after the project was implemented was organized into a Microsoft
Excel spreadsheet and then entered into IBM-SPSS (Statistic Package for the Social Science)
statistics software. Qualitative data was used to assess the effectiveness of the implementation of
the protocol in the hospital. During the information session with prescribers, a survey was
offered with three closed-ended questions and two open-ended questions to assess their
awareness about screening for metabolic complication in patients treated with SGAs.
The descriptive variables and demographic data were analyzed by calculating summary
means and standard deviations for continuous variables. For this project, Microsoft Word and
Microsoft Office Excel were used for the tables and spreadsheets. Intention-to-treat analysis was
used to evaluate by comparing the percentage of baseline parameters recorded in the chart prior
to the intervention and during the intervention. Categorical variables were analyzed by
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calculating frequencies and percentages, using the t-test. Statistical analysis to compare data in
both audits (at the beginning and end of the monitoring period) were performed using pairedsamples t-test.
The cost of planning, piloting, and implementation of this project was minimal until the
final incorporation of the metabolic syndrome monitoring protocol into the patients’ medical
charts. This author developed a metabolic monitoring protocol based on ADA and APA
recommendation guidelines in collaboration with the management of the hospital using
practicum hours.
For the protocol to be created and implemented, estimated resources include a part-time
employee equivalent (PTEE) for project coordinator position for four months. Additional cost
included $2,200 for materials, supplies, travel, food, etc. The budget for the project is shown in
Table 6. There was no funding for this project. Following the time analysis (Appendix E), a chart
was developed (Fig. 2) to identify major milestones and when these were achieved. The project
started with an assessment of the project site during September of 2018 and was completed in
April 2019.
Results
Informational sessions were held by the DNP student for nurses and mental health care
prescribers to describe the screening protocol. Participants included in the informational sessions
were eight psychiatrists, twelve nurses, one psychiatric mental health nurse practitioner, and the
chief nursing officer. A copy of the APA guidelines for metabolic screening, along with the
modified protocol for monitoring for MetS was provided regarding the metabolic syndrome
intervention. The informational sessions were held at various times and days over a three-week
period in the effort to capture all involved health care professionals.
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At the beginning of the intervention phase, an educational session was held for
psychiatric providers and nurses based on the literature search and best evidence-based practices,
and they were familiarized with a screening protocol based on ADA and APA guidelines
(Appendix C). After this information session, a survey was offered to the prescribers and staff
nurses to obtain qualitative data about their experience working with SGAs and testing for
metabolic complications. The survey that was offered to the health care providers after the
educational session was used to assess individual knowledge of metabolic complications in a
patient treated with SGAs and ADA/APA guideline’s recommendations.
The short survey included three closed-ended questions with two open-ended questions
where the participants could answer with their personal response. The response rate from
psychiatrists was very low. Only three of all nine (33.3 percent) agreed to complete the survey.
The three psychiatrists that agreed to complete the survey after taking part in the informational
sessions answered that they were familiar with the guidelines and are following ADA guideline’s
recommendations for monitoring for metabolic complications in patients treated with SGAs.
Those were the first two questions from the survey. Question three asked, “Who has the
responsibility to screen for metabolic abnormalities?” Two of the psychiatrists answered that this
is the responsibility of the psychiatrist because he or she prescribes the medications, but mostly
in outpatient settings. One psychiatrist answered that the responsibility is in conjunction with the
primary care provider (PCP). The fourth question asked what they think “are some barriers for
screening…”. The answers for this question were: “Patients are seeing a mental health provider
and PCP separately”, “Separate payment and billing the insurance twice for the same lab's tests”,
“Frequent exacerbation of symptoms that require inpatient hospitalizations”, and “Unavailable
documentation of the test results”. Question five asked for participants opinion “If a screening
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protocol for metabolic syndrome.” placed in the patient record would improve the rate of testing.
All three psychiatrists agreed that this will be “helpful”.
For the remaining six psychiatrists that did not complete the survey, the DNP student
does not have information about their refusal. The response from the nursing staff was better. Ten
RNs completed the survey with an average score of eighty-three percent with an SD of 24.9.
Seven nurses that completed the survey voiced the opinion that ADA guidelines mainly
concerned the psychiatrists and they are willing to monitor patients’ blood pressure, weight,
BMI, and waist circumference if these parameters were part of the patients’ paperwork.
The patients’ medical charts from the three adult units were reviewed by the DNP student
and the first thirty eligible patient’s charts that met the criteria were selected. The criteria were:
age eighteen years and above, and treated with at least one SGAs that had been started in the past
thirty days.
The chart audit and review were conducted weekly for ten weeks to track the percentage
of baseline monitoring tests ordered before and after the protocol had been implemented. Nurses
were involved in collecting these measurements (weight, BMI, and blood pressure). A
cumulative summary statistic, the average number of screening measures completed at pre- and
post-screening protocol placement, was used.
The family and personal history were recorded for all thirty of the selected patients (100
percent), blood pressure was recorded for twenty-seven patients (90 percent), and weight was
recorded for twenty-nine patients (96. 7 percent). BMI was one of the three parameters that had
been regularly monitored and documented on admission. These three assessments are part of the
admission paperwork and are performed for every patient admitted to the hospital, no matter
what medications he or she was treated with.
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Six of the patients (20 percent) treated with SGAs had HgA1C and eight of them (26.7
percent) had fasting lipid profile obtained prior to starting SGAs. Surprisingly, not one of the
patient’s measurements of waist circumference was done. Seventeen of the patients (56.7
percent) had a BMI of twenty-seven and greater on admission and only four of them (23.5
percent) had glucose and lipid levels ordered for them prior to starting treatment with SGAs.
Only three of the seven attending psychiatrists that had been treating these patients ordered the
blood test prior the interventions, and from these three psychiatrists, one ordered 66.7 percent of
HgA1C and 62.5 percent of the lipid tests.
After the screening protocol had been placed in patients’ charts, the final analysis with a
paired sample t-test demonstrated that the HgA1c tests that had been ordered after implementing
the protocol (M = .33, SD = .48), t = 3.808, p <.0) increased slightly compared to the preintervention HgA1c tests that had been ordered (M= .20, SD= .40), t = 2.693, p <.01). The
results are shown in Table 7.1 and Table 7.2. Prior to the intervention, only three psychiatrists
(37.5%) ordered 20% of HgA1c tests. After the screening protocol was placed the number of
psychiatrists that order the test increase to five (62.5%), and the percentage of HgA1c test that
has been ordered increase to 33%. The same tendency was observed in ordered lipid tests also.
The post-intervention lipid tests were slightly higher (M= .30, SD= .47), when compared with
the pre-intervention lipid tests (M =.26, SD=44), t=3.525, p<.01). The results are shown in
Tables 8.1 and 8.2. Three of the psychiatrists (37.5%) ordered 26 % of fasting lipid tests prior to
the interventions; after the interventions, five psychiatrists (62.5%) ordered 30% of lipids tests.
More than 50% (16) of the patients have been ordered HgA1c test and fasting lipids test.
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Interpretation/Discussion
Assessing patients for antipsychotic-associated metabolic disturbances and existing
metabolic pathology or elevated risk factors can influence medications’ choice and follow-up
treatment plans. The data analysis shows that fasting blood glucose (FBG), Hg1AC and lipids
testing remain low even post interventions. The ADA and APA guidelines recommended the
FBG, weight, waist circumference, blood pressure, and fasting lipids to be performed for every
patient who is treated with SGAs before the treatment with SGAs is initiated, at six weeks, at six
months, at twelve months, and at least annually thereafter. However, the data from the project
showed that if these tests are not incorporated in the existing hospital documentation, they are
not performed regularly.
Blood pressure, weight, and BMI were recorded in higher percentages due to the fact that
they were part of the admission assessment. Measuring waist circumference was not part of the
admission assessment and was not recorded at all. This indicator was not measured after the
implementation of the screening protocol. Slightly increased rates for Hg1AC and lipids testing
after the screening protocol was implemented show that efficient metabolic monitoring requires
an approach focused on educating psychiatrists and medical staff, and developing a system for
recording the data and defining responsibility for these tasks.
Barriers to Screening and Monitoring
Understanding causes for suboptimal metabolic screening in patients receiving atypical
antipsychotic medications could provide valuable clues on how best to solve this problem.
Overcoming the barriers to metabolic monitoring is an important aspect of process improvement
and is directly related to the patient’s outcome as it is shown in Fig. 3.

31

PROTOCOL TO MONITOR CARDIOMETABOLIC SYNDROME
Patient Barriers. Patient-related issues are persistent psychotic symptoms such as paranoia and
mania, and an alteration in cognition, which can make the patient less compliant with testing no
matter is her or she in-patient or outpatient. The access and affordability to medical care are also
barriers along with non-compliance with medical treatment (Gill, 2012). The impaired judgment
that most of the patients with a chronic mental disorder have do not allow them to recognize and
acknowledge the metabolic symptoms and to seek medical help.
Providers’ Barriers. Cohn and Sernyak (2006) suggest that insufficient medical knowledge
about the additive burden of cardiometabolic complications and not enough emphasis on the
patient’s medical needs from mental health providers are some of the reasons monitoring
guidelines are not implemented in mental health settings. However, this does not seem to be
supported by evidence. A survey conducted in 2007 by Suppes et al. on five hundred US
psychiatrists found that 97% of them were familiar with the metabolic syndrome abnormalities,
but only 78% monitored the weight of the patients, only 69% monitored glucose levels, 61%
monitored lipid levels, 52% monitored blood pressures and 16% monitored HgA1c (Mitchell,
2011).
The lowest percentage of monitoring among metabolic syndrome parameters was waist
circumference. Alberti et al. (2005) suggest that prescribers may not be aware of the importance
of waist circumference as a strong independent predictor of cardiovascular disease. Limited
medical resources for patients with severe mental illness have been blamed, as well as a lack of
time and a shortage of staff to perform these procedures (Gill, 2012). Many psychiatric care
providers do not assess patients for medical issues and do not order tests because of a lack of
time, resources, or a lack of consideration regarding the importance of waist circumference
(Mitchell, 2011).

32

PROTOCOL TO MONITOR CARDIOMETABOLIC SYNDROME
There is an ongoing debate in regards to where the responsibility lies for monitoring
metabolic abnormality in psychiatric patients receiving SGAs. Does this obligation fall on the
primary care physician or on the practitioner who actually prescribes the medications (i.e., the
psychiatrist)? Additionally, who should follow up on abnormal cardiometabolic screening
results? Some authors claim that this is not strictly the psychiatrist’s responsibly, as long as they
delegate the task and the tests were performed (Cohn, 2006).
In general, guidelines are very difficult to implement, not only due to a lack of resources
and/or time but also because of low organizational support, clinicians’ resistance to change,
concerns over the quality of the guidelines, and lack of ownership (Mitchell, 2011).
System Barriers. Overwhelming evidence exists that patients with psychiatric diagnoses receive
an inferior quality of medical care, including follow-ups for metabolic syndrome and diabetes
care (Mitchell, 2011). The fact that these patients have to see a primary care provider and a
mental health provider separately complicates the issue. Insurance coverage could also be a
serious barrier, in terms of not covering some tests, the newest antipsychotic medications with
the fewest metabolic complications, or limiting the number of health care providers and
consultants.
As the SGAs that mental health providers prescribe increase vulnerability to metabolic
syndrome, these providers need to be able to diagnose, refer for a medical consult or treat
metabolic syndrome complications associated with these medications (Parks, 2011). The largest
controlled study, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), found
that 88% of the patients with dyslipidemia were untreated, as were 62% with hypertension and
38% with diabetes (Meyer et al. 2005; Correll et al. 2007). Obviously, it is imperative that the
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mental health provider assumes responsibility for ensuring appropriate medical management and
collaborates with the primary care provider in regards to these issues.
Conclusion
Cardiometabolic syndrome remains a serious concern among patients who are treated
with atypical antipsychotic medications. There is overwhelming evidence-based data that the
majority of these medications cause significant weight gain, dyslipidemia, hyperglycemia, and
increased glucose levels that can lead to diabetes. Despite metabolic monitoring guidelines, there
is still a gap in the monitoring of metabolic syndrome of all individuals on SGAs (Velligan et al.,
2011). Implementation of screening protocols for monitoring and early detection of metabolic
syndrome abnormalities could decrease the risk of developing those abnormalities and decrease
morbidity and mortality of the patients receiving atypical antipsychotics.
This quality improvement project and the implementation of the monitoring protocol for
cardiometabolic monitoring was successful in increasing the number of baseline relevant testing
orders for a lipid panel and hemoglobin A1c in the selected patients treated with SGAs. Despite
the improvement, however, the rates of monitoring for some metabolic parameters remained low
(i.e., waist circumference). Staff nurse participants demonstrated improved knowledge about the
metabolic disturbances in patients treated with SGAs and willingness to collaborate with
psychiatric prescribers regarding metabolic screening. Some of the psychiatrists found the
metabolic screening protocol somewhat helpful for their practices. The basic screening protocol
incorporated into the patient medical record and brief staff education has potential to increase
knowledge of the staff of metabolic disturbances in patients treated with SGAs and improve
medical staff adherence to guideline recommendations, as well as improve overall patient
outcomes.
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Appendix A

Informational Session
The author of the quality improvement project provided mental health care providers with
the following information:
1.

The significance of metabolic screening for patients treated with atypical

antipsychotic medications; statistics.
2.

The ADA and APA monitoring guidelines recommendation for metabolic

monitoring of patients who are treated with SGAs.
3.

A handout with risk factors and metabolic syndrome parameters that need to be

considered.
4.

A handout with the proposed monitoring protocol base on ADA and APA’s

guidelines (2004).
5.

Overview of the quality improvement project.

6.

Survey for psychiatric providers about their experience with SGA’s and screening

for metabolic syndrome.
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Appendix B
Psychiatric Care Providers Survey
This questionnaire is part of the student quality improvement project: IMPLEMENTING
A PROTOCOL TO MONITOR CARDIOMETABOLIC SYNDROME IN PATIENTS
PRESCRIBED ATYPICAL ANTIPSYCHOTICS and all questions related to your care approach
in the management of patients on second-generation antipsychotic medications (SGAs). The
information provided by you is strictly confidential and will be seen by the DNP student and
Project Committee. You and your practice will not be identified in any reports or publications
that may result from this project.
1. Are you aware of the specific National Cholesterol Education Program metabolic
syndrome diagnostic criteria?
Yes…………………………………………….
No…………………………………………….
2. Do you consider monitoring for metabolic abnormalities (weight, BP, Lipid profile,
Fasting glucose or Hgb A1C, and waist circumference) when prescribing atypical
antipsychotics (SGAs) and how often?
Yes……………………………………………
No……………………………………………
How often……………………………….
3. Who has the responsibility to screen for metabolic abnormalities in a patient treated with
SGAs?...............................................................................................
………………………………………………………………………………………………
………………………………………………………………………………………………
4. What do you think are some barriers for screening for metabolic syndrome in patients on
SGAs?....................................................................................................................................
………………………………………………………………………………………………
………………………………………………………………………………………………
5. Do you think placing a screening protocol for metabolic syndrome in the patient’s chart
would improve the rate of monitoring for patients on SGAs therapy?
Yes……………………………………….
No…………………………………………
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Appendix C
Metabolic Monitoring Protocol
Your patient is on the following atypical antipsychotic:
___ aripiprazole (Abilify)
___ olanzapine (Zyprexa)
___ asenapine (Saphris)
___ paliperidone (Invega)
___ clozapine (Clozaril)
___ quetiapine (Seroquel)
___ iloperidone (Fanapt)
___ risperidone (Risperdal)
___ Lurasidone (Latuda)
___ ziprasidone (Geodon)
Per ADA/APA guidelines, the following monitoring parameters/labs are recommended
when a new atypical antipsychotic is started:
❖ Personal and Family History of obesity, diabetes, dyslipidemia,
hypertension, cardiovascular disease
❖ Weight
❖ Fasting Plasma Glucose
❖ Waist circumference
❖ Hemoglobin A1c
❖ Blood Pressure
❖ Fasting Lipid Profile
For patients continuing previous atypical antipsychotics, please refer to following
monitoring parameters/labs (Based on the APA/ADA Guidelines).

Personal/Family History
Weight (BMI)
Waist Circumference
Blood Pressure
Fasting Plasma Glucose
Fasting Lipid profile

Baseline
x
x
x
x
x
x

4 Weeks

8 Weeks

12 Weeks

Quarterly

x

x

x

x

x
x
x

Annually
x
x
x
x
x
x*

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association
for the Study of Obesity, Consensus Development Conference on antipsychotics drugs and obesity and diabetes. Diabetes Care 2004; 598-601

*Fasting Lipid Profile should be monitored every five years unless significant abnormalities are present. If present,
monitor annually.

ATP III Criteria for Clinical Identification of Metabolic Syndrome
Risk Factors
Abdominal Obesity
• Men
• Women
Triglycerides
HDL Cholesterol
• Men
• Women
Blood Pressure
Fasting Glucose

Defining Level
Waist Circumference
• >102 cm (>40 inches)
• >88 cm (>35 inches)
≥150 mg/dl
• <40 mg/dl
• <50 mg/dl
≥ 130/85 mmHg
≥ 110 mg/dl

If you have any questions, please contact:
Name: _____________________________________
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Appendix E
Time Analysis:
1.

Assessment of the needs: September 2018

2.

DNP Project approvals: October 2018

3.

Meeting with clinical director and staff mental health prescribers to familiarize

them with the project: September/October 2018
4.

Data collection; first patient charts’ audit; implementing of the protocol for

monitoring of metabolic abnormalities: October 2018
5.

Weekly char audit; final data collection: November 2018 through January 2019

6.

Analysis of the data: February 2019

7.

Project competition: March 2019

8.

Final report and presentation: May 2019
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Table 1
Core Criteria for Diagnosing Metabolic Syndrome¹
Central obesity

Waist circumferenceª- ethnicity-specific
plus, any two of the following:

Raised triglycerides

≥ 1.7 mmol/l (150 mg/dl) or
specific treatment for this lipid abnormality

Reduces HDL-Cholesterol

<1.03 mmol/l (40 mg/dl) in male
<1.29 mmol/l (50 mg/dl) in female or
specific treatment for this lipid abnormality

Raised Blood Pressure

Systolic: ≥130 mmHg
or Diastolic: ≥ 85 mmHg
or treatment of previously diagnosed hypertension

Raised Fasting Plasma
Glucoseᵇ

Fasting plasma glucose ≥ 5.6 mmol/l (100 mg/dl)
or previously diagnosed with Type 2 diabetes
if >5.6 mmol/l or 100 mg/dl, oral glucose tolerance test
strongly recommended but is not necessary to define
presence of the syndrome

1.Adopted from International Diabetes Federation- metabolic syndrome worldwide definition
ª If body mass index is > 30 kg/m² then central obesity can be assumed, and waist circumference
does not need to be measured.
ᵇ In clinical practice, impaired glucose intolerance is also acceptable, but all reports of the
prevalence of the metabolic syndrome should use only the fasting plasma glucose and presence
of previously diagnosed diabetes to assess this criterion.
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Table 2
Atypical Antipsychotics side effects¹
Weight
gain

Dyslipi
demia

DM

EPS Prolactin
increase

Amisulpride

+

−

+

+

Aripiprazole

−

−

−

Asenapine

+/−

+/−

Clozapine

+++

Olanzapine

Sedation QT-interval
prolongation

+++

−

−

+/−

−

+

−

−

−

−

++

−

++

+++

−

−

+++

+

+++

++

++

−

−

+++

−

Quetiapine

++

+

++

−

−

++

−

Risperidone

++

+/−

++

+

+++

+

++

Ziprasidone

+/−

−

−

−

+

−

++

+++ high incidence; ++ moderate incidence; + low incidence; − very low incidence.
1. Adapted from American Diabetes Association/American Psychiatric Association, 2004; De
Nayer et al., 2005; Cohn and Sernyak, 2006; De Hert et al., 2006; Tschoner et al., 2007; Leucht
et al., 2009).
EPS = extra-pyramidal symptoms.

48

PROTOCOL TO MONITOR CARDIOMETABOLIC SYNDROME
Table 3
SWOT Analysis
STRENGTHS
INTERNAL

WEAKNESSES

-Hardworking and dedicated staff
-Families involved with
patient care
-The staff welcomes new projects
-Hospital management
welcome nursing and advanced
practice nursing students

OPPORTUNITIES
EXTERNAL

-Hospital welcome and provide
projects for practice
improvement
-Administration and
management keep
communication lines open
-Administration and
management supportive of
the project
-Metabolic monitoring
protocol can be used as a
part of the screening process

ADA- American Diabetes Association
APA-American Psychiatric Association
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-No current metabolic
syndrome monitoring
protocol
-Inconsistencies following
ADA/APA guidelines for
metabolic screening in
patients on SGAs
-Short hospital stays

THREATS
-Psychiatrists resistant to
changes
-Psychiatrists’ mistrust of
advanced practice
nursing role
-Needs for corporate
management
approval
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Table 4
Monitoring Protocol for Managing Individuals with Normal Baseline Values at the Start
of an Episode of Care¹
Baseline

6 weeks (if
starting drug
treatment)

12 weeks (if
staring drug
treatment)

At least annually
thereafter

Medical history

X

Weight/waist/BMI

X

X

X

X

Blood pressure

X

X

X

X

Fasting glucose

X

X

X

X

Fasting lipids

X

X

X

X

Lifestyle advice

X

X

X

X

1.Adopted from De Hert, 2011.
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Table 5
Patients Data Analyses
Population Descriptors

Pre-intervention
N = 30

Sex: -male
20 (66.7%)
-female
10 (33.3%)
Age (years)
37.53
Length of stay (days)
20.73
Race: -White
21 (70%)
-Africal American
8 (26.6%)
-Other
1 (3.3%)
Comorbidities:
-Diabetes
6 (20%)
-Hypertension
8 (26.7%)
-Hyperlipidemia
4 (13.3%)
-Obesity
17 (56.7%)
-ADHD
7 (23.3%)
Weight
29 (96.7%)
Body mass index
28 (93.3%)
Waist Circumference
0
Blood pressure
27 (90%)
Fasting Blood Glucose
6 (20%)
(HgA1c)
Lipid Panel
8 (26.7%)
ADHD-Attention Deficit Hyperactive Disorder
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Post-intervention
N = 30

29 (96.7%)
28 (93.3%)
0
27 (90%)
10 (33.3%)
9 (30%)
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Table 6
Budget
Annual Cost to implement the Project
2018

2019

Gas

$ 100

$50

Paper

$50

$50

Pens, pencils, markers

$60

$40

Making copies

$500

$100

Meetings/materials

$100

$50

Miscellaneous

$100

$500

Total

$ 910

$790
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Table 7.1.
One-Sample Statistics of HgA1c Testing prior to and after Interventions
N

Mean

Std.Deviation

St. Error Mean

HgA1c ª

30

.2000

.40684

.07428

postHgA1c ᵇ

30

.3333

.47946

.08754

ª HgA1c prior interventions
ᵇ postHgA1c – HgA1c after the interventions

Table 7.2.
One -sample Test of HgA1c Testing prior to and after Interventions

t

df

HgA1cª

2.693

29

postHgA1cᵇ

3.808

29

Test Value = 0
95% Confidence Interval of the
Difference
Sig. (2-tailed)
Mean
Lower
Upper
Difference
.012
.20000
.0481
.3519
.001

ª HgA1c prior interventions
ᵇ postHgA1c – HgA1c after the interventions
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.33333

.1543

.5124
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Table 8.1.
One-Sample Statistics of Lipids Testing Prior and after Interventions
N

Mean

Std. Deviation

Std. Error Mean

Lipidsª

30

.2667

.44978

.08212

postLipids ᵇ

30

.3000

.46609

.08510

ª Lipids prior interventions
ᵇ postLipids – Lipids after the interventions

Table 8.2.
One-Sample Test of Lipids Testing Prior and after Interventions

t

df

Lipidsª

3.247

29

postLipidsᵇ

3.525

29

Test Value = 0
95% Confidence Interval of the
Difference
Sig. (2-tailed)
Mean
Lower
Upper
Difference
.003
.26667
.0987
.4346
.001

ª Lipids prior interventions
ᵇ postLipids – Lipids after the interventions
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.30000

.1260

.4740
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Structure/ Inputs
How is the care organized?
The stable elements which makeup the
system; patients, equipment, supplies,
training, environment

Process/Steps
What is done?
What happens in the interactions?
Coordination, physician orders

Outcome/Outputs
What happens to the patient’s
health?
Clinical outcomes, functional
status, cost

Fig.1. The Donabedian Model: Structure- Process-Outcome
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Task

Jun

Jul

Aug Sep Oct

Nov Dec

2018

Jan

Feb

Mar Apr May

2019

The topic finalized
Researched information and
review the literature
Gained permission to
conduct the project; wrote
the project prospectus; wrote
the protocol
Secure the necessary
supplies; gained final
approval from Southcoast
Behavioral Health

X

X

X

X

X

X

Final meeting with a medical
director
; meeting with prescribers
(psychiatrists, NPs)

X

X

Chart Review of eligible
patients
Intervention:

X

X

X

Implementing the protocol
begin
Weekly chart audit after the
protocol was implemented
and information collection
starts; continuous
implementation of metabolic
protocol monitoring

X

Analyze data and write a
project report

X

X

X

Presenting the final report to
the clinical director and staff
of the hospital

X

X

Fig.2. Timeline

57

PROTOCOL TO MONITOR CARDIOMETABOLIC SYNDROME
Family Barriers

Clinical Team Barriers

Structural/Process-of-care
Barriers
-Emotional distress
-Inadequate communication skills -Clinician turnover
-Uncertainty about
-Lack of interest
-Time constraints
patient’s preferences
-Inadequate attention to emotional -Lack of timely/regular
-Personal desires about
and moral considerations
communication
goals for the patient
-Failure to include key
-Intrafamily conflict
members of the family
-Distrust of clinicians
or of the team
Ideal Clinical Team
-Accept diverse goals of care
-Effectively communicate
prognostic information
-Present treatment options
without undue bias
-Provide emotional and moral
support

Ideal Structure/Process of Care
-Early and timely communication
-Clinician continuity
-Convenient space for meetings
-Multidisciplinary involvement

Good outcomes
-Patient-centered decisions
-Appropriate resource use

Bad outcomes
-Non-patient centered decisions
-Adverse psychiatric sequelae for
surrogates
-Inappropriate resource use

Fig.3. The Donabedian Model: Barriers; outcomes
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